12.09.25 -- 2025 Tariffs Barely Impact Europe's API Supply Chains

Cell and gene therapies are revolutionizing medicine, but outdated manufacturing methods are slowing progress. Discover how ^modernizing CGT production can unlock a treatment's full potential.

See how Codex HiCap RNA Polymerase supports the production of high-performance synthetic mRNA, paving the way for next-generation mRNA therapies.

Is your supply chain ready for a blockbuster cell and gene therapy launch? Industry leaders discuss selecting partners, managing risk, and scaling operations for maximum reach and success.

The ability to produce unlimited batches of induced mesenchymal stem cells from a single iPSC cell bank is, perhaps, one of their most alluring features.

Reducing turnaround times and sample volumes in release testing can accelerate cell therapy manufacturing, preserve product yield, and improve patient outcomes.

Here, we identify twelve critical CMC challenges that frequently threaten cell therapy development programs and provide practical strategies to overcome them.

Regulators are implementing new rules to combat counterfeit medicines. Learn how serialization, tamper-evident seals, and track-and-trace solutions protect products and patients from risk.

The existing regulatory system is ambiguous for RNA therapeutics. Leverage this Investigational New Drug (IND) guide to help accelerate and strengthen the process IND filing of novel nanomedicines.

Every choice is critical in AAV vector production. Experts share how to make the right choices, from the process and cell line, to off-the-shelf plasmids and qualified analytical methods.

When it comes to furthering AAV's potential in the wider biopharmaceutical pipeline, partnering with a CDMO that can foment an optimal analytical and manufacturing strategy is crucial.

With experience in managing assay transfers across diverse sources and development stages, we have identified five factors that can significantly impact the success of potency assay transfers.

Examine how a partner with extensive capabilities and expertise adds value to drug development and helps to solve complex formulation, analytical, and manufacturing challenges our clients face.

A rigorous, proactive approach is essential for excellence in pharmaceutical manufacturing. See how embedding rigor in systems, workflows, and workforce capabilities improves compliance and efficiency.

At this year’s Meeting on the Mesa, Viralgen's Chief Commercial Officer Andy Holt shared updates on three strategic initiatives designed to streamline gene therapy development.

By combining scientific expertise with deep functional characterization, our annotation platform helps inform manufacturing decisions and guide donor selection for allogeneic CAR-T development.

Our master and working cell banks are customized to meet your specific requirements for size, concentration, and in-process and release testing.

Our flexible partnership models empower you to scale efficiently and confidently — whether advancing a single molecule or managing a complex portfolio of therapeutic candidates.

Witness how the VBM and the LENTIVERSE™ technology platform provide a full suite of tools capable of quickly delivering state-of-the-art therapies and developing next-generation products.

Leveraging the technology, expertise, and capacity of a cell therapy CDMO is crucial to reduce timelines and lower costs as you bring your novel cell therapy from discovery to commercialization.